You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 27, 2024

CLINICAL TRIALS PROFILE FOR KOMBIGLYZE XR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for kombiglyze xr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02022007 ↗ Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis Completed AstraZeneca Phase 3 2014-03-01 The objective of the present proposal is to compare the clinical, endocrine and metabolic effects of therapy with combination saxagliptin and metformin to saxagliptin and metformin monotherapy in women with PCOS and prediabetic hyperglycemia (IFG, IGT or IFG/IGT). Saxagliptin is an oral dipeptidyl peptidase IV (DPP-4) inhibitor whose mechanism of action is to prolong the duration of blood glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels by inhibiting their degradation and thereby augmenting insulin secretion. This study will serve as a pilot investigation to open perspectives for future studies to explore the potential of combining anti-diabetic drugs with different mechanisms of action in in patients with PCOS and impaired glucose regulation (IGR), especially ones for whom standard treatment with metformin is less effective.
NCT02022007 ↗ Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis Completed Woman's Phase 3 2014-03-01 The objective of the present proposal is to compare the clinical, endocrine and metabolic effects of therapy with combination saxagliptin and metformin to saxagliptin and metformin monotherapy in women with PCOS and prediabetic hyperglycemia (IFG, IGT or IFG/IGT). Saxagliptin is an oral dipeptidyl peptidase IV (DPP-4) inhibitor whose mechanism of action is to prolong the duration of blood glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels by inhibiting their degradation and thereby augmenting insulin secretion. This study will serve as a pilot investigation to open perspectives for future studies to explore the potential of combining anti-diabetic drugs with different mechanisms of action in in patients with PCOS and impaired glucose regulation (IGR), especially ones for whom standard treatment with metformin is less effective.
NCT02491333 ↗ The RCT of Acupuncture on PCOS Combined With IR Unknown status Karolinska Institutet Phase 3 2015-08-01 The objectives of this randomized controlled trial are to compare insulin sensitivity following true acupuncture + placebo metformin (Group 1) vs sham acupuncture + placebo metformin (Group 2) vs sham acupuncture + metformin (Group 3) in women with PCOS and IR.
NCT02491333 ↗ The RCT of Acupuncture on PCOS Combined With IR Unknown status The University of Hong Kong Phase 3 2015-08-01 The objectives of this randomized controlled trial are to compare insulin sensitivity following true acupuncture + placebo metformin (Group 1) vs sham acupuncture + placebo metformin (Group 2) vs sham acupuncture + metformin (Group 3) in women with PCOS and IR.
NCT02491333 ↗ The RCT of Acupuncture on PCOS Combined With IR Unknown status The First Affiliated Hospital of Guangzhou Medical University Phase 3 2015-08-01 The objectives of this randomized controlled trial are to compare insulin sensitivity following true acupuncture + placebo metformin (Group 1) vs sham acupuncture + placebo metformin (Group 2) vs sham acupuncture + metformin (Group 3) in women with PCOS and IR.
NCT06107153 ↗ Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control Recruiting University of Basrah N/A 2023-11-01 In this study, we aim to explore the beneficial effect of early short-term (two weeks), self-titrated, basal-only insulin therapy on the degree of glycemic control over 1-year follow through a prospective cohort.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for kombiglyze xr

Condition Name

Condition Name for kombiglyze xr
Intervention Trials
Polycystic Ovary Syndrome 2
Disorder of Glucose Regulation 1
Insulin Resistance 1
Type2diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for kombiglyze xr
Intervention Trials
Polycystic Ovary Syndrome 2
Diabetes Mellitus, Type 2 1
Diabetes Mellitus 1
Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for kombiglyze xr

Trials by Country

Trials by Country for kombiglyze xr
Location Trials
Iraq 2
China 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for kombiglyze xr
Location Trials
Louisiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for kombiglyze xr

Clinical Trial Phase

Clinical Trial Phase for kombiglyze xr
Clinical Trial Phase Trials
Phase 3 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for kombiglyze xr
Clinical Trial Phase Trials
Completed 1
Recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for kombiglyze xr

Sponsor Name

Sponsor Name for kombiglyze xr
Sponsor Trials
The University of Hong Kong 1
The First Affiliated Hospital of Guangzhou Medical University 1
University of Basrah 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for kombiglyze xr
Sponsor Trials
Other 5
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.